StemCell Institute Logo

StemCell Institute

7096 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区虎ノ門一丁目21番19号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

StemCell Institute is a premier private cord blood bank based in Japan, boasting over 25 years of expertise and a market-leading share of over 99%. Specializing in the collection and storage of umbilical cord blood and tissue, the institute offers a safe, painless collection process immediately after birth. Its state-of-the-art facilities ensure the preservation of vital stem cells, which are pivotal in regenerative medicine and potential treatments for conditions like leukemia, cerebral palsy, and autism spectrum disorders. With more than 80,000 cord blood units stored and recognized as ISO 9001 certified, StemCell Institute is committed to advancing medical research and enhancing future treatment options for families. Its innovative services include the storage of umbilical cord-derived mesenchymal stem cells, further expanding therapeutic possibilities.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for StemCell Institute. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-01 08:41
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-06-26 08:37
Regulatory News Service
臨時報告書
Japanese 23.2 KB
2025-06-24 08:36
Regulatory News Service
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-24 08:35
Regulatory News Service
確認書
Japanese 8.7 KB
2025-06-24 08:33
Annual Report
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 1017.9 KB
2025-06-02 08:39
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2025-05-01 09:38
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2025-04-01 08:27
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.8 KB
2025-03-04 08:55
Regulatory News Service
訂正自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 31.8 KB
2025-03-03 07:31
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2025-02-05 03:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2025-02-04 07:59
Regulatory News Service
臨時報告書
Japanese 26.7 KB
2025-01-14 07:33
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2024-11-14 07:33
Regulatory News Service
確認書
Japanese 8.7 KB
2024-11-14 07:31
Interim Report
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 189.9 KB

Automate Your Workflow. Get a real-time feed of all StemCell Institute filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for StemCell Institute via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK